Global Chronic Inflammation Treatment Market - 2023-2030

Global Chronic Inflammation Treatment Market - 2023-2030

The global chronic inflammation treatment market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030 growing with a CAGR of XX% during the forecast period 2023-2030.

The chronic inflammation treatment market trends show rising product launches owing to the rising technological advancements. Inflammation that lasts for a few months to years is known as chronic inflammation treatment. The cause of the trauma and the ability of the body to repair and undo the harm are the main determinants of the intensity and effects of chronic inflammation treatment.

Furthermore, rising adoption of products for chronic inflammation treatment due to the rising availability of tests or medications and increase in the number of nonspecific proliferative chronic inflammation treatment in the market, and an increase in the research and development is driving up the chronic inflammation treatment market size.

The market is experiencing a growth demand for products from North American areas as a result of the rising advancements in this field. With significant competitors like Pfizer Inc., NodThera, Abcentra, and Halia Therapeutics, Inc. actively operating in the market.

Dynamics

Growing Advancements and Clinical Trials by Key Players Drive the Growth of the Chronic Inflammation Treatment Market

Chronic inflammatory illnesses have increased in incidence and prevalence during the past few decades, particularly in Westernized nations. In order to reduce inflammation and pain, several NSAIDs are utilized; however, these anti-inflammatory drugs have a wide range of severe side effects, as opposed to plant-based natural medicines, which have anti-inflammatory medicinal properties with few to no negative side effects.

With their high drug loading capacity and potential for good target selectivity for specific cells and tissues, nanoparticles are a novel type of drug delivery system that may enhance therapeutic bioavailability and improve pharmacokinetics and pharmacodynamics (PKPD). The market is predicted to take the lead throughout the forecast period as a consequence of the aforementioned claims.

Rising Research and Development and Novel Product Launches Creates Opportunities for the Growth of the Market

As a result of years of study, a number of major manufacturers are now developing novel products and releasing them for therapeutic purposes, which is fostering the expansion of the chronic inflammation treatment market. Several treatments have been approved by the regulatory authorities for management of chronic inflammation.

For instance, on February 12, 2021, the supplemental Biologics License Application for PANZYGA - ifas 10% Liquid Preparation to treat adult patients with the uncommon neurological condition known as chronic inflammatory demyelinating polyneuropathy (CIDP), which affects the peripheral nerves, was approved by the U.S. Food and Drug Administration (FDA). In order to better serve patients' clinical needs, PANZYGA is the one and only intravenous immunoglobulin (IVIg) that has two FDA-approved maintenance dosage alternatives for CIDP.

Side Effects of Chronic Inflammation Treatment Medications will hamper the growth of the market

Several side effects are linked with the chronic inflammation treatment medications which can restrain the market’s growth. The most common gastrointestinal adverse effects are abdominal pain, nausea, and diarrhea, which are experienced by 20% to 30% of patients and frequently go away on their own. Lactic acidosis is a more serious consequence that only occurs in about 1.5 per 100,000 persons each year.

Although metformin is generally thought to be rather safe, it does have one major (though uncommon) side effect known as lactic acidosis. This illness develops when the blood contains an excessive amount of lactate, a chemical produced by the muscles and red blood cells. Your lactic acid level is typically low.

For more details on this report – Request for Sample

Segment Analysis

The global chronic inflammation treatment market is segmented based type, medications, chronic inflammatory disease type, distribution channel and region.

Owing to High Demand, the Metaformin from Medication Segment Accounted for Approximately 37.1% of the Chronic Inflammation Treatment Market Share

The metaformin category from medications held the largest market share in 2022 and is expected to maintain its dominance over the forecast period due to a growth in inflammatory disorders worldwide. Throughout the world, the biguanide metformin acts as the first-line pharmaceutical treatment for type II diabetic mellitus (T2D).

Metformin is the most adaptable and therapeutically significant medication to date. The glycemic control brought on by the reduction of hepatic glucose output, the suppression of autoimmune inflammation by controlling T-cell balance, the decrease of cardiovascular mortality, the prevention of cancer, and dementia are just a few of the most significant therapeutic benefits of metformin.

Since metformin has been shown to reduce inflammation, it is a desirable medicine to test for a variety of different disorders. Additionally, leukocytes from PCOS participants with lower amounts of reactive oxygen species, TNF and IL-6 and higher levels of glutathione were found. Recent research demonstrates that metformin has an instant anti-inflammatory effect in addition to reducing Chronic Inflammation Treatment by enhancing metabolic parameters.

Geographical Penetration

North America Accounted for Approximately 42.3% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment

Due to the rising need for chronic inflammation treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for chronic inflammation treatment.

Increasing expenditure on healthcare and rising adoption among patients, advancement of technologies for medications, and increase in pharmaceutical business establishment across the region are also contributing to the growth of chronic inflammation treatment market share of this region.

It is also anticipated that the main healthcare organizations' and enterprises' collaborative research projects as well as new product development, which constantly seeks to improve available simulation training alternatives, will contribute to the expanding demand. Individuals are becoming more aware of various advanced chronic inflammatory disorders and their medications that are being utilized for treatment purposes, leading to the expansion of the market in this region. The above-mentioned factors further proves the dominance of North America on a global scale.

Competitive Landscape
The major global players in the chronic inflammation treatment market include Pfizer Inc., NodThera, Abcentra, Evommune, Inc., Sterna biologicals, Halia Therapeutics, Inc., Amgen Inc., AstraZeneca, Takeda Pharmaceutical Company Limited and Annexon, Inc. among others.

COVID-19 Impact Analysis

Russia Ukraine Conflict Analysis

Due to the low prevalence as well as absence of major market participants in this region, it is predicted that the Russia-Ukraine conflict will not have a significant effect on the worldwide chronic inflammation treatment market. The growth of the global chronic inflammation treatment market, however, is anticipated to be relatively unaffected by the import and export of raw materials over the forecast period.

By Type
• Nonspecific Proliferative
• Granulomatous Inflammation
Foreign Body Granuloma
Infectious Granuloma

By Medications
• Metformin
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Naproxen
Ibuprofen
Aspirin
• Statins
Simvastatin
Rosuvastatin
• Corticosteroids
Cortisone
Prednisone
• Herbal Supplements

By Chronic Inflammation Disease Type
• Diabetes
• Cardiovascular Diseases
• Arthritis and Joint Diseases
• Chronic Obstructive Pulmonary Disease (COPD)
• Allergies
• Others

By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• On August 7, 2023, the enrollment of participants in the Phase I study (NCT05447546) assessing HT-6184, Halia Therapeutics' lead asset, for chronic inflammation treatment has been completed, according to the company, which is developing novel medications to treat a wide range of diseases caused by Chronic Inflammation Treatment. The NLRP3 inflammasome activity is inhibited by the first pharmacological candidate, HT-6184, which targets the protein NEK7 via an allosteric mechanism.
• On April 26,, 2023, a $50 million Series B round of financing for the clinical-stage biotechnology startup Evommune, Inc.'s research and development of novel therapies for inflammatory illnesses. Arix Bioscience, a new investor, along with EQT Life Sciences, SymBiosis, and several current investors co-led the fundraising. several participants included Amplitude Ventures, another new investor, as well as Series A investors Andera Partners and Pivotal bioVenture Partners.
• On June 20, 2023, HYQVIA (Recombinant Human Hyaluronidase with Immune Globulin Infusion 10%) was studied as a maintenance therapy in older individuals with chronic inflammatory demyelinating polyneuropathy (CIDP), and Takeda released the entire results of the pivotal Phase 3 ADVANCE-CIDP 1 clinical trial. When HYQVIA was compared to placebo, the results revealed a clinically significant decrease in the relapse rate, and additional study revealed a prolonged time until recurrence.

Why Purchase the Report?
• To visualize the global chronic inflammation treatment market segmentation based on type, medications, chronic inflammatory disease type, distribution channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of chronic inflammation treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global chronic inflammation treatment market report would provide approximately 69 tables, 71 figures and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies